Israel-based in vitro diagnostics (IVD) firm, Picodya, has announced that its B-Matrix multiplexed point-of-care testing (xPOCT) systems are being implemented in government laboratories across the US.
The adoption by the National Institute of Health (NIH) comes as part of a bid to establish a backlog of immunobiological countermeasures in preparation for another pandemic, allowing for large-scale global serologic surveillance and real-time monitoring of the immune status of entire human populations.
The NIH initiative, named PREMISE and headed up by the National Institute of Allergy and Infectious Diseases (NIAID), launched in 2021 and saw the body working alongside Picodya to install the B-Matrix systems at NIAID Vaccine Research Centers and laboratories to detect reactivity to multiple potential pandemic sources.
Picodya has said that its platform is the first xPOCT IVD solution that performs both molecular and immunoassays from many body fluids on a single platform and that it is certified to carry out immunoassays and molecular tests in conditions including Covid-19, influenza, HBV, EBV, prostate cancer and cardiologic markers.
CEO of Picodya, Tzvika Barkai, said: “With our knowledge of the devastating impact of Covid-19 on global health and following years of research collaboration with the NIH for crisis preparedness, we are proud to proceed with the next phase of this important partnership.
“We remain dedicated to enabling timely, precise, and comprehensive disease diagnosis capabilities to optimize potential outcomes. We plan to introduce the B-Matrix solution to additional research labs across the US, followed by the broader clinical market.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
PREMISE, an acronym for Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology, will use the devices to screen and analyse samples from animal reservoirs and symptomatic humans to identify new and re-emerging pathogens.
Daniel Douek, director of the Premise initiative at the NIH, added: “Over the past two years, our team has established a global network of partner sites to meet the PREMISE objective of increasing immunologic monitoring of targeted human populations across the globe.
“We appreciate the significant benefits the B-Matrix platform could bring to the PREMISE program, enabling multiplex testing at scale with high accuracy.”
Research published by GlobalData’s Medical Device Intelligence Centre valued the worldwide diagnostic imaging market at $31.9bn in 2023, with that figure expected to rise to more than $45bn by the end of 2030.
It comes after NIAID’s other initiative, Project NextGen, received $1.4bn from the US Department of Health and Human Services (HHS) to facilitate the development of new vaccines for Covid-19.